Stockreport

Stoke Therapeutics: FDA Delay Doesn't Change Zorevunersen's Opportunity [Seeking Alpha]

Stoke Therapeutics, Inc.  (STOK) 
Last stoke therapeutics, inc. earnings: 11/12 08:00 am Check Earnings Report
PDF This approach gives Zorevunersen disease-modifying features, which I believe will ultimately make it a very competitive asset for Dravet if approved. I believe Zorevu [Read more]